Phase 3
Intervention Type
Intravenous (IV) Injection
Funder Type

Drug Details

Remdesivir is a novel antiviral drug in the class of nucleotide analogs. 

Study Purpose

The studies will evaluate two dosing durations of remdesivir. One study will randomize approximately 400 patients with severe clinical manifestations of COVID-19 to receive either five or 10 days of remdesivir. The second study will randomize approximately 600 patients with moderate clinical manifestations of disease to receive five or 10 days of remdesivir or standard of care alone. 

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >